Alex Biese

Last week, the FDA provided updates on two cancer therapies. In this episode, we discuss those decisions and more.

Patients with melanoma play a vital role in their own post-surgical care, as one expert from Dana-Farber Cancer Institute explained to CURE®.

Nearly 40% of patients who received treatment for cervical cancer were still being prescribed outpatient opioids for pain management six months later, according to recently published study findings.

Award-winning journalist applied the same dedication that served her award-winning reporting in support of her own survival following a diagnosis of stage 4 anaplastic thyroid cancer.

Patients continue to be enrolled in a study evaluating the dual-action androgen receptor inhibitor ONCT-534 for the treatment of patients with advanced prostate cancer who are relapsed or refractory to approved androgen receptor pathway inhibitors (ARPIs).

“When we talk about recurrence of melanoma, we actually worry more about what we cannot see, what's on the inside,” Dr. Justine V. Cohen of the Dana-Farber Cancer Institute told CURE®.

The Food and Drug Administration has accepted a supplemental Biologics License Application (sBLA) intended to convert the accelerated approval granted to Tivdak (tisotumab vedotin-tftv) in 2021 to full approval for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after first-line therapy.

The year 2024 is now underway. After a busy 2023, we’re now looking back at some of the oncology headlines from the new year.

Vd1-gd T cells, a rare type of immune cell, have been found to potentially predict how likely it is that certain patients with advanced skin cancer will be responsive to treatment via immunotherapy, according to recently published research.

Patients with relapsed/refractory mantle cell lymphoma described by one expert as “older, sicker and more heavily pretreated” than those previously studied experienced impressive responses to treatment with CAR-T cell therapy Tecartus.

Researchers have found the CAR-T cell therapy Breyanzi (lisocabtagene maraleucel) to be a cost-effective second-line treatment for patients with relapsed and refractory diffuse large B-cell lymphoma as the drug’s cost rises.

From Jimmy Buffett's death to the chemo shortage and cannabis use in cancer care, here is a look back at some of our most popular oncology stories from 2023.

Dr. Stephanie Berg of Dana-Farber Cancer Institute and Harvard Medical School discusses the need to be mindful of quality of life when treating prostate cancer.

Experts look back on the year in the news regarding bispecific antibodies for the treatment of B-cell lymphomas including CLL and SLL.

The Food and Drug Administration has granted an Orphan Drug Designation to SLS009, a CDK9 inhibitor, for the treatment of patients with relapsed/refractory peripheral T-cell lymphomas.

Dr. Heather Parsons of Dana-Farber Cancer Institute explains how a liquid biopsy could help patients with breast cancer and their care teams learn vital information.

Long-term cancer survivors experience diabetes at similar rates as individuals who are cancer-free, but cancer survivors with diabetes face a potentially higher risk of death, researchers have found.

Dr. Douglas Tremblay of the Ichan School of Medicine explains the necessity of cytoreductive therapy for patients with MPNs such as essential thrombocythemia and polycythemia vera.

The Food and Drug Administration (FDA) has granted Fast Track Designation to the investigational adenovirus CAN-2409 plus prodrug Valtrex for the treatment of patients with pancreatic ductal adenocarcinoma.

One expert explained how nurses have “opportunities to get to talk with patients and their loved ones in ways that you don't (get) when you're in the time crunch of an appointment with your oncologist,” and how that can impact end-of-life care.

Patients with relapsed/refractory large B-cell lymphoma treated with CAR-T cell therapy and bendamustine chemotherapy, experienced lower rates of survival and response as well as shorter times until progression, according to recent study findings.

The Food and Drug Administration recently approved treatment for some patients with neuroblastoma, kidney cancer and bladder cancer. Elsewhere, a cancer vaccine made headlines for the treatment of patients with melanoma.

Those caring for loved ones with cancer are “at risk for becoming overwhelmed or becoming so burdened to the point of exhaustion or being sick themselves,” one expert says.

A treatment combination of Sarclisa, Kyprolis, Revlimid and dexamethasone demonstrated a complete response in patients who were newly diagnosed with multiple myeloma.

Dr. Stephanie Berg of the Dana-Farber Cancer Institute and Harvard Medical School discussed the recent EMARK trial which resulted in the FDA’s approval of Xtandi for non-metastatic castration-sensitive prostate cancer (nmCSPC) with biochemical recurrence at high risk for metastasis.

One expert explains how patients’ wishes for their end-of-life care can change with time, making those conversations with caregivers “not a one-time, sit-down discussion.”

“I have found many survivors to be very strong women who seem like they have things under control but it’s always important for family and friends to check in,” television personality, author and breast cancer survivor Giuliana Rancic told CURE.

Patients with advanced-stage melanoma continue to experience reduced risk of recurrence or death following treatment with a combination of mRNA vaccine mRNA-4157 (V940) and Keytruda, an anti-PD-1 therapy, according to recent study findings.

The Food and Drug Administration has approved Welireg for patients with advanced renal cell carcinoma, a type of kidney cancer, following treatment with a PD-1 or PD-L1 inhibitor and a VEGF-TKI.

An expert explains the significance of the recent approval of Xtandi for non-metastatic castration-sensitive prostate cancer (nmCSPC) with biochemical recurrence at high risk for metastasis (high-risk BCR) by the Food and Drug Administration.